OncoSec Medical Incorporated (ONCS) Raised to Sell at ValuEngine
ValuEngine upgraded shares of OncoSec Medical Incorporated (NASDAQ:ONCS) from a strong sell rating to a sell rating in a research report report published on Thursday morning.
Separately, Maxim Group restated a buy rating and issued a $5.00 price objective on shares of OncoSec Medical in a report on Tuesday, October 10th. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $5.33.
OncoSec Medical (NASDAQ ONCS) traded up $0.17 during mid-day trading on Thursday, hitting $2.26. 9,225,200 shares of the stock traded hands, compared to its average volume of 5,097,307. OncoSec Medical has a 1 year low of $0.88 and a 1 year high of $2.55.
OncoSec Medical (NASDAQ:ONCS) last announced its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.05). sell-side analysts predict that OncoSec Medical will post -0.86 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “OncoSec Medical Incorporated (ONCS) Raised to Sell at ValuEngine” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2017/11/12/oncosec-medical-incorporated-oncs-raised-to-sell-at-valuengine.html.
About OncoSec Medical
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for OncoSec Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.